Boehringer In­gel­heim once again turns to RNAi for new MASH ther­a­pies

Boehringer In­gel­heim is part­ner­ing with Chi­na-based biotech Suzhou Ri­bo Life Sci­ence and its Swe­den-based unit Ri­bo­cure Phar­ma­ceu­ti­cals to de­vel­op siR­NA ther­a­pies for meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER